Akouos Appoints Stacy Price as Chief Technical Officer
01 November 2021 - 10:00PM
Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company
dedicated to developing potential gene therapies for individuals
living with disabling hearing loss worldwide, today announced the
appointment of Stacy Price as chief technical officer. Ms. Price
brings to Akouos more than 25 years of experience managing clinical
and commercial biotechnology manufacturing and technical operations
for a wide range of therapeutic modalities, including gene therapy.
At Akouos, she will be responsible for the strategy and operations
of vector development and manufacturing, as well as device
development and engineering.
“We are excited to welcome Stacy to Akouos as we continue to
advance the AK-OTOF and AK-antiVEGF programs towards our planned
IND submissions next year,” said Manny Simons, Ph.D., M.B.A.,
co-founder, president, and chief executive officer. “Her extensive
operations background, including facilities and construction,
Chemistry, Manufacturing, and Controls (CMC), and information
management, will add critical experience and skills to our senior
leadership team. We look forward to working with Stacy to
demonstrate the broad applicability of our precision genetic
medicines platform as we move towards clinical development and
ultimately commercialization of our pipeline.”
Ms. Price was most recently senior vice president of technical
operations at Ziopharm Oncology, where she was accountable for
development and delivery of CMC strategy for cell and combination
gene therapy products, and for establishing the company’s clinical
manufacturing capability. Prior to Ziopharm, Ms. Price was head of
pharmaceutical development operations at Shire, where she led CMC
program management as well as laboratory and pilot plant
operations, and set overall operations strategy. She holds a Master
of Science in Biochemical Engineering from Tufts University.
“It is a privilege for me to lead a team of experts establishing
the infrastructure and capabilities for manufacturing genetic
medicines at Akouos,” said Ms. Price. “I am excited to join Akouos
as we work toward achieving the company’s shared mission of healthy
hearing available to all.”
About AkouosAkouos is a precision genetic
medicine company dedicated to developing gene therapies with the
potential to restore, improve, and preserve high-acuity physiologic
hearing for individuals living with disabling hearing loss
worldwide. Leveraging its precision genetic medicine platform that
incorporates a proprietary adeno-associated viral (AAV) vector
library and a novel delivery approach, Akouos is focused on
developing precision therapies for forms of sensorineural hearing
loss. Headquartered in Boston, Akouos was founded in 2016 by
leaders in the fields of neurotology, genetics, inner ear drug
delivery, and AAV gene therapy.ContactsMedia:Katie
Engleman, 1ABkatie@1abmedia.com
Investors:Courtney Turiano, Stern Investor
RelationsCourtney.Turiano@sternir.com
Akouos (NASDAQ:AKUS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akouos (NASDAQ:AKUS)
Historical Stock Chart
From Apr 2023 to Apr 2024